NCT00380367View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

PHASE3CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

May 3, 2007

Primary Completion Date

February 4, 2008

Study Completion Date

February 4, 2008

Conditions

Papillomavirus Infections

Interventions

BIOLOGICAL

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00380367 - Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) | Biotech Hunter | Biotech Hunter